Medical progress: Nonalcoholic fatty liver disease

New England Journal of Medicine

Volumn 346, Issue 16, 2002, Pages 1221-1231

  Angulo, Paul ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTIVIRUS AGENT; BETAINE; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DIDANOSINE; ESTROGEN; FIALURIDINE; GEMFIBROZIL; GLUCOCORTICOID; METFORMIN; METHOTREXATE; PERHEXILINE MALEATE; TAMOXIFEN; TETRACYCLINE; TROGLITAZONE; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZIDOVUDINE;

ALCOHOL CONSUMPTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; FATTY LIVER; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; BIOPSY; ECHOGRAPHY; LIVER; LIVER FUNCTION TEST; PATHOLOGY; RADIOGRAPHY; WEIGHT REDUCTION;

BIOPSY; FATTY LIVER; HUMANS; LIVER; LIVER FUNCTION TESTS; PREVALENCE; RISK FACTORS; WEIGHT LOSS;

EID: 0037129380     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra011775     Document Type: Review

References (95)

1. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
2. Nonalcoholic fatty liver disease
3. Fatty liver hepatitis and cirrhosis in obese patients
4. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis
5. Alcohollike liver disease in nonalcoholics: A clinical and histologic comparison with alcohol-induced liver disease
6. Nonalcoholic steatohepatitis: A study of 49 patients
7. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
8. Nonalcoholic steatohepatitis: An expanded clinical entity
9. The natural history of nonalcoholic fatty liver: A follow-up study
10. Idiopathic steatohepatitis in childhood: A multicenter retrospective study
11. Nonalcoholic steatohepatitis: Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
12. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
13. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
14. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
15. Fatty liver - An additional and treatable feature of the insulin resistance syndrome
16. Liver fibrosis in overweight patients
17. Nonalcoholic steatohepatitis in children
18. Non-alcoholic steatohepatitis in children and adolescents
19. Prevalence of and risk factors for hepatic steatosis in northern Italy
20. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
21. Liver pathology in morbidly obese patients with and without diabetes
22. The metabolically obese, normal-weight individual revisited
23. Fatty infiltration of liver in hyperlipidemic patients
24. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds
25. Prevalence of fatty liver in a general population of Okinawa, Japan
26. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty
27. Prevalence of fatty liver in Japanese children and relationship to obesity: An epidemiological ultrasonographic survey
28. Frequency of abnormalities detected by abdominal ultrasound among Japanese adults
29. Liver involvement in obese children: Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population
30. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients
31. Nonalcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the U.S. population
32. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
33. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994
34. Liver diseases and diabetes mellitus
35. Liver pathology in diabetes mellitus and morbid obesity: Clinical, pathological and biochemical considerations
36. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
37. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
38. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis
39. Insulin resistance-associated hepatic iron overload
40. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
41. Hepatic iron and nonalcoholic fatty liver disease
42. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease
43. Transient focal fatty liver infiltration mimicking liver metastasis
44. Focal manifestations of diffuse liver disease at MR imaging
45. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis
46. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
47. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
48. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
49. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
50. Leptin deficiency enhances sensitivity to endotoxin-induced lethality
51. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
52. High molecular weight components are main constituents of Mallory bodies isolated with fluorescence activated cell sorter
53. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis
54. Chemotactic activity of hydroxyalkenals on rat neutrophils
55. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function
56. Processing/activation of CPP32-like proteases is involved in transforming growth factor β1-induced apoptosis in rat hepatocytes
57. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines
58. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor
59. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse
60. Glutathione depletion by hyperphagia-induced obesity
61. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells
62. Association of nonalcoholic fatty liver disease with insulin resistance
63. Rad: A member of the Ras family overexpressed in muscle of type II diabetic humans
64. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus
65. Modulation of insulin activities by leptin
66. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
67. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance
68. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism
69. Mitochondrial abnormalities in non-alcoholic steatohepatitis
70. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
71. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study
72. Steatohepatitis: A tale of two "hits"?
73. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?
74. Drinking habits as cofactors of risk for alcohol induced liver damage
75. Factors determining cirrhosis in alcoholic liver disease
76. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study
77. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
78. Hepatic effects of dietary weight loss in morbidly obese subjects
79. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
80. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
81. Effect of weight reduction on hepatic abnormalities in overweight patients
82. Nonalcoholic steatohepatitis in obesity: A reversible condition
83. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
84. Persistent hyperaminotransferasemia resolving after weight reduction in obese children
85. Liver morphology and function tests in obesity and during total starvation
86. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass
87. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
88. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
89. Metformin in non-alcoholic steatohepatitis
90. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: A pilot study
91. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
92. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study
93. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
94. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis